Epoprostenol (prostacyclin) and severe arterial disease: a double-blind trial

J. J. F. Belch, B. McArdle, J. G. Pollock, C. D. Forbes, A. Mckay, P. Leiberman, G. D. O. Lowe, C. R. M. Prentice

    Research output: Contribution to journalArticle

    103 Citations (Scopus)

    Abstract

    A 96 h infusion of epoprostenol (prostacyclin) or placebo was given as a treatment for rest pain to 28 patients with severe peripheral arterial disease. 24 h after the end of the infusion patients given epoprostenol had significantly less pain and took fewer analgesics tablets than did the controls. In some patients the epoprostenol effect lasted for over 1 month.
    Original languageEnglish
    Pages (from-to)315-317
    Number of pages3
    JournalLancet
    Volume321
    Issue number8320
    DOIs
    Publication statusPublished - 1983

    Cite this

    Belch, J. J. F., McArdle, B., Pollock, J. G., Forbes, C. D., Mckay, A., Leiberman, P., Lowe, G. D. O., & Prentice, C. R. M. (1983). Epoprostenol (prostacyclin) and severe arterial disease: a double-blind trial. Lancet, 321(8320), 315-317. https://doi.org/10.1016/S0140-6736(83)91625-2